The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review

Cancer

Volumn 120, Issue 18, 2014, Pages 2824-2838

  Fong, Zhi Ven ^a   Tanabe, Kenneth K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Consensus guidelines; Hepatocellular carcinoma; Recommendations; Review

Indexed keywords

SORAFENIB;

ADVANCED CANCER; ARTIFICIAL EMBOLISM; ASIA; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SCREENING; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ECHOGRAPHY; EUROPE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HIGH RISK PATIENT; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; RADIOFREQUENCY ABLATION; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMIC THERAPY; TREATMENT PLANNING; UNITED STATES; COMPARATIVE STUDY; CONSENSUS GUIDELINES; EVIDENCE BASED MEDICINE; LIVER TUMOR; PROGNOSIS; RECOMMENDATIONS;

CONSENSUS GUIDELINES; HEPATOCELLULAR CARCINOMA; RECOMMENDATIONS; REVIEW;

ASIA; CARCINOMA, HEPATOCELLULAR; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; LIVER NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; UNITED STATES;

EID: 84908037166     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28730     Document Type: Review

References (134)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Poon RT, Fan ST, Lo CM, et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235:373-382.
3. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatocellu-lar carcinoma confirmation, treatment, and survival in Surveillance, Epidemiology, and End Results registries, 1992-2008. Hepatology. 2012;55:476-482.
4. Cha C, Fong Y, Jarnagin WR, et al. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 2003;197:753-758.
5. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-1491.
6. Nathan H, Bridges JF, Schulick RD, et al. Understanding surgical decision making in early hepatocellular carcinoma. J Clin Oncol. 2011;29:619-625.
7. El-Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158-166.
8. Nathan H, Segev DL, Bridges JF, et al. Influence of nonclinical factors on choice of therapy for early hepatocellular carcinoma. Ann Surg Oncol. 2013;20:448-456.
9. Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992;16:132-137.
10. Sheu JC, Sung JL, Chen DS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterol-ogy. 1985;89:259-266.
11. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47.
12. Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonogra-phy in transplant patients. J Ultrasound Med. 2001;20:99-104.
13. Sato T, Tateishi R, Yoshida H, et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int. 2009;3:544-550.
14. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130: 417-422.
15. Trevisani F, Cantarini MC, Labate AM, et al. Surveillance for hepatocel-lular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol. 2004;99:1470-1476.
16. Trinchet JC, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3-and 6-month periodicities. Hepatology. 2011;54:1987-1997.
17. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 2013. Fort Washington, PA: NCCN; 2013.
18. Poon D, Anderson BO, Chen LT, et al. Management of hepatocel-lular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10:1111-1118.
19. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepa-tocellular carcinoma. Hepatology. 2005;42:1208-1236.
20. Roskams T. Anatomic pathology of hepatocellular carcinoma: impact on prognosis and response to therapy. Clin Liver Dis. 2011;15:245-259, vii-x.
21. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.
22. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocel-lular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797-1801.
23. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepato-cellular carcinoma in Alaska Natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000;32:842-846.
24. Villanueva A, Minguez B, Forner A, et al. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 2010;61:317-328.
25. Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepa-tocellular carcinoma. Cancer Res. 2009;69:7385-7392.
26. Zhang B, Yang B. Combined alpha fetoprotein testing and ultraso-nography as a screening test for primary liver cancer. J Med Screen. 1999;6:108-110.
27. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonogra-phy, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006;101:513-523.
28. Ngan H. Lipiodol computerized tomography: how sensitive and specific is the technique in the diagnosis of hepatocellular carcinoma? Br J Radiol. 1990;63:771-775.
29. Bartolozzi C, Lencioni R, Caramella D, et al. Small hepatocellular carcinoma. Detection with US, CT, MR imaging, DSA, and Lipio-dol-CT. Acta Radiol. 1996;37:69-74.
30. Bizollon T, Rode A, Bancel B, et al. Diagnostic value and tolerance of Lipiodol-computed tomography for the detection of small hepa-tocellular carcinoma: correlation with pathologic examination of explanted livers. J Hepatol. 1998;28:491-496.
31. Llovet JM, Fuster J, Bruix J; Barcelona Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepa-tocellular carcinoma. Liver Transpl. 2004;10:S115-S120.
32. Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion. 2003;67:138-145.
33. Silva MA, Hegab B, Hyde C, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008;57:1592-1596.
34. Parikh P, Malhotra H, Jelic S; EMSO Guidelines Working Group. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(suppl 2):ii27-ii28.
35. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypo-vascular hepatocellular carcinoma. Hepatology. 2005;42:27-34.
36. Muhi A, Ichikawa T, Motosugi U, et al. Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI. J Magn Reson Imaging. 2011;34:326-335.
37. Kudo M. Diagnostic imaging of hepatocellular carcinoma: recent progress. Oncology. 2011;81(suppl 1):73-85.
38. Inoue T, Kudo M, Hatanaka K, et al. Imaging of hepatocellular carcinoma: qualitative and quantitative analysis of postvascular phase contrast-enhanced ultrasonography with Sonazoid. Comparison with superparamagnetic iron oxide magnetic resonance images. Oncology. 2008;75(suppl 1):48-54.
39. Katyal S, Oliver JH 3rd, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216:698-703.
40. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocel-lular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918-928.
41. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62-67.
42. Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocel-lular carcinoma. Hepatology. 2010;51:1274-1283.
43. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepato-cellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging score (JIS score). J Gastroenterol. 2003;38:207-215.
44. Lu W, Dong J, Huang Z, et al. Comparison of 4 current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastro-enterol Hepatol. 2008;23:1874-1878.
45. Vauthey JN, Ribero D, Abdalla EK, et al. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J Am Coll Surg. 2007; 204:1016-1027; discussion 1027-1018.
46. Minagawa M, Ikai I, Matsuyama Y, et al. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13, 772 patients in Japan. Ann Surg. 2007;245:909-922.
47. Cillo U, Bassanello M, Vitale A, et al. The critical issue of hepato-cellular carcinoma prognostic classification: which is the best tool available? J Hepatol. 2004;40:124-131.
48. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44: 723-731.
49. Wang JH, Changchien CS, Hu TH, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma-survival analysis of 3892 patients. Eur J Cancer. 2008;44:1000-1006.
50. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338.
51. Cho YK, Chung JW, Kim JK, et al. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transar-terial chemoembolization. Cancer. 2008;112:352-361.
52. Huitzil-Melendez FD, Capanu M, O'Reilly EM, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol. 2010;28:2889-2895.
53. Colombo M, Raoul JL, Lencioni R, et al. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. Eur J Gastroenterol Hepatol. 2013;25:639-651.
54. Schwartz ME, Sung M, Mor E, et al. A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis. J Am Coll Surg. 1995;180:596-603.
55. Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg. 2002;235:533-539.
56. Roayaie S, Blume IN, Thung SN, et al. A system of classifying mi-crovascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137:850-855.
57. Poon RT, Fan ST, Lo CM, et al. Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg. 2002;236:602-611.
58. Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocel-lular carcinoma. Gastroenterology. 2008;134:1908-1916.
59. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1, 803 consecutive cases over the past decade. Ann Surg. 2002;236:397-406; discussion 406-397.
60. Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-6 hepatectomies without mortality in 8 years. Arch Surg. 2003;138: 1198-1206; discussion 1206.
61. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181-200.
62. Cheung TT, Poon RT, Yuen WK, et al. Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience. Ann Surg. 2013;257:506-511.
63. Nguyen KT, Gamblin TC, Geller DA. World review of laparoscopic liver resection-2, 804 patients. Ann Surg. 2009;250:831-841.
64. Imamura H, Sano K, Sugawara Y, et al. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg. 2005;12:16-22.
65. Lau H, Man K, Fan ST, et al. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hep-atectomy. Br J Surg. 1997;84:1255-1259.
66. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellu-lar carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996;111:1018-1022.
67. Cucchetti A, Piscaglia F, Caturelli E, et al. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg. Oncol. 2009;16:413-422.
68. Kubota K, Makuuchi M, Kusaka K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997;26:1176-1181.
69. Shoup M, Gonen M, D'Angelica M, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg. 2003;7:325-330.
70. Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg. 2005;140:450-457; discussion 457-458.
71. Kingham TP, Scherer MA, Neese BW, et al. Image-guided liver surgery: intraoperative projection of computed tomography images utilizing tracked ultrasound. HPB (Oxford). 2012;14:594-603.
72. Kingham TP, Jayaraman S, Clements LW, et al. Evolution of image-guided liver surgery: transition from open to laparoscopic procedures. J Gastrointest Surg. 2013;17:1274-1282.
73. Yeh CN, Lee WC, Chen MF. Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: 2 decades of experience at Chang Gung Memorial Hospital. Ann Surg Oncol. 2003;10: 1070-1076.
74. Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003; 237:208-217.
75. Hemming AW, Reed AI, Howard RJ, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003;237: 686-691; discussion 691-683.
76. Abulkhir A, Limongelli P, Healey AJ, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg. 2008;247:49-57.
77. Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012;255:405-414.
78. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
79. Koniaris LG, Levi DM, Pedroso FE, et al. Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma? Ann Surg. 2011;254:527-537; discussion 537-528.
80. Yeh H, Smoot E, Schoenfeld DA, Markmann JF. Geographic inequity in access to livers for transplantation. Transplantation. 2011;91:479-486.
81. Rahman A, Assifi MM, Pedroso FE, et al. Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? A meta-analysis. J Gastrointest Surg. 2012;16:1897-1909.
82. Poon RT. Optimal initial treatment for early hepatocellular carcinoma in patients with preserved liver function: transplantation or resection? Ann Surg Oncol. 2007;14:541-547.
83. Adam R, Azoulay D. Is primary resection and salvage transplantation for hepatocellular carcinoma a reasonable strategy? Ann Surg. 2005;241:671-672.
84. Adam R, Azoulay D, Castaing D, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg. 2003;238:508-518; discussion 518-509.
85. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepato-cellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-1403.
86. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502-509; discussion 509-511.
87. Mazzaferro V. Results of liver transplantation: with or without Milan criteria? Liver Transpl. 2007;13:S44-S47.
88. Ioannou GN, Perkins JD, Carithers RL. Jr Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology. 2008;134:1342-1351.
89. Bruix J, Fuster J, Llovet JM. Liver transplantation for hepatocellu-lar carcinoma: Foucault pendulum versus evidence-based decision. Liver Transpl. 2003;9:700-702.
90. Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant. 2008;8:839-846.
91. Morioka D, Egawa H, Kasahara M, et al. Outcomes of adult-to-adult living donor liver transplantation: a single institution's experience with 335 consecutive cases. Ann Surg. 2007;245:315-325.
92. Goldberg SN, Gazelle GS, Compton CC, et al. Treatment of intra-hepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer. 2000;88:2452-2463.
93. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82-89.
94. Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004;240:900-909.
95. Lu DS, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005;41:1130-1137.
96. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg. 1999;230:1-8.
97. Fong ZV, Palazzo F, Needleman L, et al. Combined hepatic arterial embolization and hepatic ablation for unresectable colorectal metastases to the liver. Am Surg. 2012;78:1243-1248.
98. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122-130.
99. Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54:1151-1156.
100. Lin SM, Lin CJ, Lin CC, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma <4 cm. Gastroenterology. 2004;127:1714-1723.
101. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-328.
102. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235-240.
103. Lu MD, Kuang M, Liang LJ, et al. [Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial]. Zhonghua Yi Xue Za Zhi. 2006;86:801-805.
104. Feng K, Yan J, Li X, et al. A randomized controlled trial of radio-frequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57:794-802.
105. Llovet JM, Vilana R, Bru C, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology. 2001;33:1124-1129.
106. Huang J, Hernandez-Alejandro R, Croome KP, et al. Radiofrequency ablation versus surgical resection for hepatocellular carcinoma in Childs A cirrhotics-a retrospective study of 1, 061 cases. J Gastrointest Surg. 2011;15:311-320.
107. Zhou Y, Zhao Y, Li B, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma [serial online]. BMC Gastroenterol. 2010;10:78.
108. Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2010;17:171-178.
109. Groeschl RT, Pilgrim CH, Hanna EM, et al. Microwave ablation for hepatic malignancies: a multi-institutional analysis [published online ahead of print October 3, 2013]. Ann Surg. 2013.
110. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30:969-977.
111. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739.
112. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171.
113. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-442.
114. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6-25.
115. Chan AO, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter intra-arterial lipiodol chemoem-bolization in patients with hepatocellular carcinoma. Cancer. 2002; 94:1747-1752.
116. Molinari M, Kachura JR, Dixon E, et al. Transarterial chemoem-bolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. Clin Oncol (R Coll Radiol). 2006; 18:684-692.
117. Llado L, Virgili J, Figueras J, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer. 2000;88:50-57.
118. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of trans-arterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461-469.
119. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71-81.
120. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507, e492.
121. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52-64.
122. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepa-tocellular carcinoma: results of the PRECISION V study. Cardio-vasc Intervent Radiol. 2010;33:41-52.
123. Dhanasekaran R, Kooby DA, Staley CA, et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembo-lization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). J Surg Oncol. 2010;101:476-480.
124. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced he-patocellular carcinoma. N Engl J Med. 2008;359:378-390.
125. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
126. Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res. 2011;4:40-44.
127. Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of singleagent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer. 2009;115:428-436.
128. Chiu J, Tang YF, Yao TJ, et al. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. Cancer. 2012;118:5293-5301.
129. Camma C, Cabibbo G, Petta S, et al. Cost-effectiveness of sorafe-nib treatment in field practice for patients with hepatocellular carcinoma. Hepatology. 2013;57:1046-1054.
130. Fong ZV, Tanabe KK. Comparison of melanoma guidelines in the USA, Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol. 2014;170:20-30.
131. Fong ZV, Winter JM. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. 2012;18:530-538.
132. Zhu AX, Chabner BA, Tanabe KK. New trends and novel treatment for hepatocellular carcinoma: a global perspective. Oncologist. 2010;15(suppl 4):1-4.
133. Hoshida Y, Fuchs BC, Tanabe KK. Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets. 2012;12:1129-1159.
134. Tanabe KK, Chiocca EA. "Infectious" optimism for treatment of hepatocellular carcinoma. Mol Ther. 2013;21:722-724.